Vijaya Diagnostic Centre Ltd
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.[1]
- Market Cap ₹ 12,517 Cr.
- Current Price ₹ 1,220
- High / Low ₹ 1,250 / 595
- Stock P/E 99.6
- Book Value ₹ 69.8
- Dividend Yield 0.08 %
- ROCE 18.9 %
- ROE 17.2 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 17.5 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of Nifty Smallcap 250 BSE Allcap Nifty MidSmallcap 400 BSE Healthcare Nifty 500 Multicap 50:25:25
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
238 | 279 | 329 | 367 | 451 | 450 | 525 | 581 | |
160 | 187 | 196 | 204 | 251 | 271 | 313 | 347 | |
Operating Profit | 78 | 92 | 133 | 163 | 200 | 179 | 212 | 234 |
OPM % | 33% | 33% | 40% | 44% | 44% | 40% | 40% | 40% |
5 | 9 | 12 | 11 | 13 | 15 | 19 | 15 | |
Interest | 4 | 4 | 15 | 15 | 16 | 21 | 24 | 24 |
Depreciation | 23 | 26 | 48 | 50 | 52 | 61 | 55 | 60 |
Profit before tax | 56 | 70 | 82 | 110 | 144 | 111 | 152 | 165 |
Tax % | 36% | 31% | 25% | 24% | 25% | 25% | 25% | |
35 | 49 | 61 | 83 | 108 | 83 | 115 | 124 | |
EPS in Rs | 78.17 | 108.02 | 135.13 | 18.28 | 10.60 | 8.15 | 11.20 | 12.11 |
Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 12% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 13% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 8% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 29% |
1 Year: | 101% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 19% |
Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 |
Reserves | 162 | 211 | 273 | 356 | 460 | 535 | 643 | 706 |
26 | 36 | 156 | 137 | 183 | 248 | 250 | 265 | |
31 | 40 | 41 | 36 | 58 | 57 | 59 | 100 | |
Total Liabilities | 224 | 292 | 475 | 533 | 711 | 850 | 962 | 1,081 |
102 | 137 | 264 | 261 | 364 | 517 | 582 | 626 | |
CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 16 |
Investments | 77 | 73 | 58 | 32 | 59 | 144 | 254 | 302 |
42 | 80 | 143 | 231 | 254 | 161 | 117 | 137 | |
Total Assets | 224 | 292 | 475 | 533 | 711 | 850 | 962 | 1,081 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
62 | 77 | 109 | 128 | 155 | 163 | 175 | |
-100 | -91 | -34 | -129 | -127 | -108 | -139 | |
-7 | 8 | -28 | -48 | -25 | -41 | -43 | |
Net Cash Flow | -44 | -7 | 46 | -49 | 4 | 13 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 14 | 14 | 9 | 7 | 8 | 7 | 9 |
Inventory Days | 24 | 19 | 23 | 16 | 22 | 12 | 26 |
Days Payable | 152 | 175 | 163 | 133 | 108 | 172 | 178 |
Cash Conversion Cycle | -115 | -142 | -130 | -110 | -79 | -153 | -143 |
Working Capital Days | -22 | -28 | -30 | -11 | -22 | -25 | -16 |
ROCE % | 33% | 27% | 27% | 28% | 18% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Nov - Schedule of Analyst/Institutional Investor meetings.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 12 Nov
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 11 Nov
- Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Nov
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
7 Nov - Audio recording of Q2 FY25 earnings conference call.
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024TranscriptNotesPPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Dec 2023TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
Market Leadership
The company is the largest integrated diagnostic chain in South India. [1] It was among the first in South India to offer PET-CT scans. [2]